Arteriolar niche used by breast cancer cells to prepare for metastasis

NewsGuard 100/100 Score

More than 43,000 American women will die from breast cancer this year. Most of those deaths will occur after the cancer has spread to other organs, a process called metastasis. This involves at least five major steps. Two early steps are invasion of the basement membrane and cell migration, and then a movement of the cancer cell through the wall and into a blood vessel or lymph vessel to begin its journey.

By examining estrogen receptor-positive breast cancer tissues from women, Bin Ren, M.D., Ph.D., associate professor of surgery at the University of Alabama at Birmingham, has now found, for the first time, evidence of a heretofore unnoticed location for breast cancer stem cells in the tumor microenvironment at the cell migration stage. The cancer stem cells appear to accumulate near a tumor arteriole, the small branch of the artery just before capillaries.

Ren calls this the arteriolar niche, and he says it may be an important tumor vascular microenvironment to prepare cancer cells for metastasis, not only in breast cancer but also in other highly angiogenic cancers such as glioblastoma, lung cancer, malignant melanoma and pancreatic neuroendocrine cancers.

Breast cancer stem cells -; a sub-population of the cancer cells -; are the most aggressive for metastasis, growth and drug resistance.

In Ren's study, published in the journal Communications Biology (Nature), the researchers found evidence of cross-talk between the breast cancer stem cells and arteriolar endothelial cells, using the lysophosphatidic acid/protein kinase D, or the LPA/PKD-1 signaling pathway. This signaling pathway was observed to promote cancer stem cell features and potential development of the arteriolar niche by using human breast cancer tissues, mouse breast cancer models, and vascular endothelial cells from genetically engineered mice and cell cultures.

From their findings, the researchers propose a mechanistic model. Bidirectional interactions -; using LPA/PKD-1 signaling -; promote arteriolar differentiation of endothelial cells within the tumor microenvironment, self-renewal of cancer stem cells, and breast cancer progression and metastasis, likely through differential regulation of CD36 transcription.

We think this niche is important, and it may exist in other cancers with a rich growth of new blood vessels. These studies indicate that the LPA/PKD-1 signaling may play an essential role in tumor progression and spread to other organs such as the lungs by nurturing the development of an arteriolar niche to enhance cancer stem cell self-renewal and directly promoting stemness features of cancer cells. Targeting the LPA/PKD-1 CD36 signaling pathway may have therapeutic potential to curb tumor progression and metastasis by disrupting the arteriolar niche and effectively eliminating cancer stem cells."

Bin Ren, M.D., Ph.D., Associate Professor of Surgery, University of Alabama at Birmingham

Source:
Journal reference:

Jiang, Y., et al. (2021) Development of an arteriolar niche and self-renewal of breast cancer stem cells by lysophosphatidic acid/protein kinase D signaling. Communications Biology. doi.org/10.1038/s42003-021-02308-6.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
FDA approval of Anktiva heralds a new era in the treatment of BCG-unresponsive non–muscle-invasive bladder cancer